Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02680301 · ClinicalTrials.gov registry record · Phase 4
Topical Steroid Formulation and Wet Wraps
A Phase 4 study of Dermatitis, Atopic, sponsored by Seton Healthcare Family.
- Completed
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT02680301 is a Phase 4 study of Dermatitis, Atopic that has completed, run by Seton Healthcare Family. The registered enrollment target is 40 participants, below the 396-participant average among 29 other Dermatitis, Atopic trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02680301, a Phase 4 study of Dermatitis, Atopic, has completed, sponsored by Seton Healthcare Family.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to 1. Compare efficacy of 0.1% triamcinolone containing wet wrap as an ointment or as a cream formulation in patients with moderate to severe atopic dermatitis 2. The relative patient/subject acceptance and adherence will also be compared between the two wet wrap types
Conditions Studied
Interventions
- DRUG 0.1% triamcinolone CREAM
- DRUG 0.1% triamcinolone OINTMENT
Study Locations (1)
Texas
- Specially for Children Dermatology - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2016-03 |
| Est. Completion | 2018-06-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02680301
The ClinicalTrials.gov registry entry for NCT02680301 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 396-participant average among 29 other Dermatitis, Atopic trials with a reported enrollment target (90% lower). The listed sponsor is Seton Healthcare Family, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dermatitis, Atopic appearing as the primary indexed condition, and to 2 interventions - of which 0.1% triamcinolone CREAM is the first listed.
NCT02680301 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT02680301 about?
NCT02680301 is a clinical study titled "Topical Steroid Formulation and Wet Wraps". The purpose of this study is to 1. Compare efficacy of 0.1% triamcinolone containing wet wrap as an ointment or as a cream formulation in patients with moderate to severe atopic dermatitis 2. The relative patient/subject acceptance and adherence will also be compared between the two wet wrap types
What is the current status of trial NCT02680301?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2016-03. Estimated completion is 2018-06-01.
What conditions does trial NCT02680301 study?
This clinical trial studies the following conditions: Dermatitis, Atopic.
What interventions are being tested in trial NCT02680301?
The interventions under investigation include: 0.1% triamcinolone CREAM (DRUG), 0.1% triamcinolone OINTMENT (DRUG).
Who is sponsoring clinical trial NCT02680301?
This trial is sponsored by Seton Healthcare Family, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02680301 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dermatitis, Atopic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis
ACTIVE NOT RECRUITING · Phase 4
-
Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Treating Pediatric Patients With Atopic Dermatitis
COMPLETED · Phase 4
-
The Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in Patients With Atopic Dermatitis
RECRUITING · NA
-
A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Effects of Treatments on Atopic Dermatitis
RECRUITING · Phase 2
-
Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.